DekaBank Deutsche Girozentrale Makes New $61,000 Investment in Twist Bioscience Co. (NASDAQ:TWST)

DekaBank Deutsche Girozentrale purchased a new stake in shares of Twist Bioscience Co. (NASDAQ:TWST) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 1,287 shares of the company’s stock, valued at approximately $61,000.

Other hedge funds have also recently made changes to their positions in the company. BNP Paribas Financial Markets raised its position in Twist Bioscience by 34.8% in the 1st quarter. BNP Paribas Financial Markets now owns 171,823 shares of the company’s stock worth $5,895,000 after purchasing an additional 44,349 shares during the period. UBS Group AG grew its stake in shares of Twist Bioscience by 106.4% during the fourth quarter. UBS Group AG now owns 213,467 shares of the company’s stock valued at $7,868,000 after buying an additional 110,036 shares during the last quarter. SageView Advisory Group LLC purchased a new position in shares of Twist Bioscience in the first quarter worth about $1,144,000. Susquehanna Fundamental Investments LLC bought a new stake in shares of Twist Bioscience in the 1st quarter valued at about $300,000. Finally, Sei Investments Co. boosted its holdings in Twist Bioscience by 32.7% during the 1st quarter. Sei Investments Co. now owns 223,555 shares of the company’s stock valued at $7,670,000 after acquiring an additional 55,124 shares during the period.

Twist Bioscience Stock Performance

Twist Bioscience stock opened at $46.44 on Friday. Twist Bioscience Co. has a fifty-two week low of $14.42 and a fifty-two week high of $60.90. The stock has a market cap of $2.72 billion, a price-to-earnings ratio of -13.82 and a beta of 1.76. The stock’s 50 day simple moving average is $47.27 and its two-hundred day simple moving average is $43.05.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings results on Friday, August 2nd. The company reported ($1.47) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.71). The firm had revenue of $81.50 million during the quarter, compared to analysts’ expectations of $77.40 million. Twist Bioscience had a negative return on equity of 32.17% and a negative net margin of 74.63%. Twist Bioscience’s revenue for the quarter was up 27.7% on a year-over-year basis. During the same period in the previous year, the company earned ($1.01) earnings per share. On average, analysts predict that Twist Bioscience Co. will post -3.13 earnings per share for the current year.

Insider Activity at Twist Bioscience

In other Twist Bioscience news, CEO Emily M. Leproust sold 1,114 shares of the company’s stock in a transaction dated Tuesday, July 2nd. The shares were sold at an average price of $48.00, for a total value of $53,472.00. Following the sale, the chief executive officer now owns 504,732 shares in the company, valued at $24,227,136. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other news, CEO Emily M. Leproust sold 1,114 shares of the business’s stock in a transaction that occurred on Tuesday, July 2nd. The stock was sold at an average price of $48.00, for a total value of $53,472.00. Following the sale, the chief executive officer now directly owns 504,732 shares of the company’s stock, valued at approximately $24,227,136. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Dennis Cho sold 709 shares of Twist Bioscience stock in a transaction on Monday, August 5th. The shares were sold at an average price of $39.93, for a total value of $28,310.37. Following the transaction, the insider now owns 78,996 shares of the company’s stock, valued at approximately $3,154,310.28. The disclosure for this sale can be found here. Insiders sold a total of 15,125 shares of company stock valued at $664,784 in the last three months. Company insiders own 3.92% of the company’s stock.

Analyst Upgrades and Downgrades

TWST has been the topic of a number of analyst reports. The Goldman Sachs Group lifted their price target on Twist Bioscience from $45.00 to $55.00 and gave the stock a “buy” rating in a research note on Tuesday, July 9th. Robert W. Baird raised their price target on shares of Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a report on Monday, August 5th. TD Cowen upped their price objective on shares of Twist Bioscience from $55.00 to $65.00 and gave the company a “buy” rating in a research note on Thursday, June 13th. Barclays cut their target price on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a research note on Monday, August 5th. Finally, Guggenheim assumed coverage on Twist Bioscience in a research report on Tuesday, June 4th. They set a “buy” rating and a $53.00 price target for the company. One analyst has rated the stock with a sell rating and eight have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $48.22.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.